Retinal Neurodegeneration In Type 2 Diabetes Mellitus Detected by Optical

Status Not yet recruiting

Clinical Trial Summary

Evaluation of retinal neurodegeneration in patients with type 2 diabetes mellitus (DM2) without diabetic retinopathy or with mild non proliferative diabetic retinopathy

Clinical Trial Description

Retinal complications in diabetes mellitus (DM) patients were typically considered part of a vascular process. However, recent studies suggest that ocular degeneration in DM might be caused by 2 different conditions: vasculopathy and neuropathy . For some authors, neuropathy observed in the retina of DM patients might be a part of an underlying polyneuropathy ; for others, however, neuropathic changes might precede microvascular alterations . Axons of retinal ganglion cells compose the retinal nerve fiber layer (RNFL) in the retina and then form the optic nerve connecting the eyeball and brain. Retinal nerve fiber layer (RNFL) loss is recognized as an important neurodegenerative sign in glaucoma. Thinning of the RNFL has also been found in multiple sclerosis, Parkinson's disease and Alzheimer's disease, indicating neurodegeneration of the retina. If RNFL thinning is significant in diabetic patients with preclinical diabetic retinopathy, evaluation of peripapillary RNFL thickness would be very important, because early detection and treatment of diabetic retinopathy is critical to reduce the risk of blindness Optical coherence tomography (OCT) has been introduced into clinical practice as the most noninvasive and objective method to visualize the retina, showing an amount of detail that resembles histological specimens. Initially, OCT was applied to detect complications of DR (edema macular or epiretinal membrane). Later on, it allowed quantitative and qualitative measurements of retinal thickness and segmentation of all intraretinal layers. OCT might detect early retinal neurodegenerative changes, and thus help define which diabetic patients may be at risk to develop DR. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04808804
Study type	Observational
Source	Assiut University
Contact	Emel Saad Tawadrous, MBBCh
Phone	+201284854021
Email	emelsaad@ymail.com
Status	Not yet recruiting
Phase
Start date	June 2021
Completion date	June 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03671772` - Progression of Prodromal Markers of α-synucleinopathy Neurodegeneration in the FDRs of Patients With RBD
Recruiting	`NCT04480333` - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831	Phase 1
Completed	`NCT01312597` - Effects of Flavonoids on Cognitive Performance in Healthy Young Adults	Phase 2
Completed	`NCT03064607` - Neurodegeneration in Newborns After Anesthetics
Not yet recruiting	`NCT01476228` - EEG Objectification in Neuropsychiatry	N/A
Recruiting	`NCT05516719` - Longitudinal Investigation of I2BS in PD
Recruiting	`NCT04048603` - Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior Disorder
Completed	`NCT04894981` - Comparison of Power Wheelchair Driving Performance Under Immersive and Non-immersive Conditions With Drivers With Neurological Disorders	N/A
Active, not recruiting	`NCT05982860` - The Effects of the MIND Diet on Oxidative Stress, Inflammation and Neurodegenerative Risk Biomarkers	N/A
Not yet recruiting	`NCT06088355` - Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease	N/A
Not yet recruiting	`NCT06147596` - Heading in Football: Impact on Neural Blood Biomarkers
Recruiting	`NCT05388630` - Microbiome, Anxiety and Cognitive Orientation Study
Recruiting	`NCT04032626` - MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients	Phase 2
Recruiting	`NCT05516732` - Serotonin Release in Premotor and Motor PD
Completed	`NCT04637217` - Retinal Neurodegenerative and Vascular Changes in Diabetic Patients
Completed	`NCT02661789` - Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression	N/A
Recruiting	`NCT05468905` - China Longitudinal Aging and Cognitive Impairment Study
Active, not recruiting	`NCT06150495` - Glycemic Control and Retinal Microvascular Changes
Recruiting	`NCT04255758` - Acute Effects of Vigorous-intensity Aerobic Exercise on Glymphatic Flow in Healthy Adults	N/A
Completed	`NCT02983708` - Neuroregenerative Potential of Intravenous G-CSF and Autologous Peripheral Blood Stem Cells	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Retinal Neurodegeneration In Type 2 Diabetes Mellitus Detected by Optical Coherence Tomography

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms